A Phase 4 interventional study of capecitabine [Xeloda] in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 46 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-03.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 179 studies testing capecitabine in Colorectal Neoplasms — 24 open to participants now, 32 under way, 7 of them phase 3. Capecitabine · Colorectal Neoplasms.
Among the 179 studies testing capecitabine in Colorectal Neoplasms, this one is the 30th largest by enrollment of the 173 interventional ones that give a count, is one of 5 that started in 2007, is one of 8 in phase 4, and was the 63rd registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →24 of the 179 studies testing capecitabine in Colorectal Neoplasms are open now, in 9 countries. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
Gruppo Oncologico del Nord-Ovest · Sites in France, Germany, Italy and 1 more country
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
Nizhny Novgorod Regional Clinical Oncology Center · Sites in Russian Federation
Ages 70–90
Henry Ford Health System · Sites in United States
Ages 18+
By country, each count listing its studies:
Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
179 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 124 · Phase 3 37 · Phase 4 8
First in 1998; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 228 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 55 across the 173 interventional studies. Of the 111 that completed or were terminated, 36 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 179 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
111 studies in Colorectal Neoplasms by Hoffmann-La Roche: 3 open now, 7 under way, none of them phase 3. Of 99 finished, 52 (53%) have results posted.
Among the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, this one is the 21st largest by enrollment of the 77 interventional ones that give a count, is one of 5 that started in 2007, is one of 8 in phase 4, and was the 22nd registered.
Hoffmann-La Roche’s Colorectal Neoplasms studies by the year they started, since 1998.
9 of the studies testing capecitabine in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05700656The Netherlands Cancer InstituteGalunisertib Combined With Capecitabine in Advanced CRC With PM | 2026-12 |
| NCT06065371Henry Ford Health SystemSacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | 2026-12 |
| NCT07229846Yanqiao ZhangA Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation | 2027-02 |
| NCT07570914Tianjin Medical University Cancer Institute and HospitalHepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases | 2027-05-30 |
| NCT07051785Liu HuangFruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer | 2027-07-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 179 studies testing capecitabine in Colorectal Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 111 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
This single arm study will evaluate the safety profile of Xeloda as monotherapy for adjuvant treatment of colon cancer. All patients will receive Xeloda 1250mg/m2 p.o. twice daily as intermittent treatment (3 week cycles consisting of 2 weeks of treatment followed by 1 week without treatment). The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: capecitabine [Xeloda]
1250mg/m2 po bid on days 1-14 of each 3 week cycle
Percentage of Participants With an Adverse Event (AE), Serious AE, or Death Due to an AE
The postmarketing safety profile of capecitabine was evaluated by collection of AEs, clinical laboratory data, vital signs, and other findings from physical examination. Abnormalities in these findings were captured as AEs, defined as any untoward medical occurrence in a study participant regardless of the suspected cause. Serious AEs were those which, at any dose, met one or more of the following criteria: resulted in fatality, were life-threatening, necessitated new or prolonged existing hospitalization, produced persistent or significant disability, resulted in congenital anomaly or birth defect, were considered medically significant, or required intervention to prevent any of the aforementioned outcomes. Those specific serious AEs which resulted in fatality were also reported separately. The percentage of participants with an AE, serious AE, or AE resulting in death was calculated as \[number of participants with event divided by number analyzed\] multiplied by 100.
Time frame: Up to 25 weeks (from Baseline to the end of safety follow-up)
Percentage of Participants With Early Withdrawal or Discontinuation Due to an AE
The postmarketing safety profile of capecitabine was evaluated by collection of AEs, clinical laboratory data, vital signs, and other findings from physical examination. Abnormalities in these findings were captured as AEs, defined as any untoward medical occurrence in a study participant regardless of the suspected cause. The percentage of participants with early withdrawal or treatment discontinuation due to an AE was calculated as \[number of participants with event divided by number analyzed\] multiplied by 100.
Time frame: Up to 25 weeks (from Baseline to the end of safety follow-up)
| Milestone | Capecitabine |
|---|---|
| Started | 228 |
| Completed | 151 |
| Not completed | 77 |
| Withdrew: Disease progression | 13 |
| Withdrew: Personal reasons | 22 |
| Withdrew: Lost to follow-up | 7 |
| Withdrew: Protocol violation | 16 |
| Withdrew: Adverse event | 19 |
The postmarketing safety profile of capecitabine was evaluated by collection of AEs, clinical laboratory data, vital signs, and other findings from physical examination. Abnormalities in these findings were captured as AEs, defined as any untoward medical occurrence in a study participant regardless of the suspected cause. Serious AEs were those which, at any dose, met one or more of the following criteria: resulted in fatality, were life-threatening, necessitated new or prolonged existing hospitalization, produced persistent or significant disability, resulted in congenital anomaly or birth defect, were considered medically significant, or required intervention to prevent any of the aforementioned outcomes. Those specific serious AEs which resulted in fatality were also reported separately. The percentage of participants with an AE, serious AE, or AE resulting in death was calculated as \[number of participants with event divided by number analyzed\] multiplied by 100.
| percentage of participants | Capecitabine |
|---|---|
| Any AE | 56.1 |
| Serious AE | 6.1 |
| Death due to an AE | 0.4 |
The postmarketing safety profile of capecitabine was evaluated by collection of AEs, clinical laboratory data, vital signs, and other findings from physical examination. Abnormalities in these findings were captured as AEs, defined as any untoward medical occurrence in a study participant regardless of the suspected cause. The percentage of participants with early withdrawal or treatment discontinuation due to an AE was calculated as \[number of participants with event divided by number analyzed\] multiplied by 100.
| percentage of participants | Capecitabine |
|---|---|
| Early withdrawal due to an AE | 8.3 |
| Discontinuation due to an AE | 10.1 |
Collected over Up to 25 weeks (from Baseline to the end of safety follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Capecitabine | — | 14/228 (6.1%) | 81/228 (35.5%) |
| Event | Capecitabine |
|---|---|
| Myocardial infarctionCardiac disorders | 2/228 |
| Abdominal abscessGastrointestinal disorders | 1/228 |
| Colon cancerGastrointestinal disorders | 1/228 |
| IleusGastrointestinal disorders | 1/228 |
| Inguinal herniaGastrointestinal disorders | 1/228 |
| StomatitisGastrointestinal disorders | 1/228 |
| DeathGeneral disorders | 1/228 |
| Disease progressionGeneral disorders | 1/228 |
| CholecystitisHepatobiliary disorders | 1/228 |
| MetastasisNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/228 |
| Event | Capecitabine |
|---|---|
| Palmar-plantar erythrodysaesthesia syndromeNervous system disorders | 48/228 |
| DiarrhoeaGastrointestinal disorders | 20/228 |
| HyperbilirubinaemiaBlood and lymphatic system disorders | 17/228 |
| VomitingGastrointestinal disorders | 12/228 |
Safety Population: All enrolled participants who received a dose of study medication.
| Age, Continuous(years) | Capecitabine |
|---|---|
| Mean | 58 ± 9 |
| Sex: Female, Male(Participants) | Capecitabine |
|---|---|
| Female | 125 |
| Male | 103 |
The record gives a start of Jul 2007, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Capecitabine